# US 2026/0077048 A1 · Pharmaceutical compositions comprising meloxicam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077048 A1
- Document ID: US20260077048A1
- Status: Published application
- Kind: A1
- Application number: 19/367,653
- Filed: 2025-10-23
- Published: 2026-03-19
- Earliest claimed: 2015-02-10
- Assignees: Axsome Therapeutics, Inc.
- Applicants: Axsome Therapeutics, Inc.
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20260077048A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 47/02: Inorganic compounds
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 25/06: Antimigraine agents
- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- C08L 5/16: Cyclodextrin; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

## Claims

### Claim 1

A method of reducing the Tmax of rizatriptan, comprising orally administering a monolayer tablet to a human patient experiencing a migraine, wherein the monolayer tablet comprises 20 mg of meloxicam, 10 mg of rizatriptan, sodium bicarbonate, and a sulfobutylether-β-cyclodextrin (SBEβCD), wherein administering the monolayer tablet to the human patient results in the human patient having a Tmax of rizatriptan that is about 0.75 hours.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human patient has a history of inadequate response to prior migraine treatments.

### Claim 3 (depends on 1)

The method of claim 1, wherein the monolayer tablet is orally administered with food.

### Claim 4 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains about 50 mg to about 150 mg of the SBEβCD.

### Claim 5 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains about 100 mg of the SBEβCD.

### Claim 6 (depends on 1)

The method of claim 1, wherein the molar ratio of the SBEβCD to meloxicam is about 0.5 to about 2.

### Claim 7 (depends on 1)

The method of claim 1, wherein the molar ratio of the SBEβCD to meloxicam is about 0.8 to about 1.2.

### Claim 8 (depends on 1)

The method of claim 1, wherein the molar ratio of the SBEβCD to meloxicam is about 1.

### Claim 9 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains the SBEβCD that is in a weight ratio to the rizatriptan that is within a range of about 1 to about 100.

### Claim 10 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains the SBEβCD that is in a weight ratio to the rizatriptan that is about 10.

### Claim 11 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains 400 mg to 600 mg of sodium bicarbonate.

### Claim 12 (depends on 1)

The method of claim 1, wherein the monolayer tablet contains 500 mg of sodium bicarbonate.
